Board of Directors

John Haurum

John is a non-executive Director in several European biotech companies, including AgomAb, Synklino, Synact, Storm and Neophore. Prior, he was the CEO of F-star in Cambridge, UK (2012-2018), where he built a successful biotech company that initiated two clinical trials in oncology and generated more than €200M in non-dilutive revenue. From 2010 to 2012, he

Mike Lee

Mike is a founding partner of Redmile Group, LLC. Prior to Redmile, Mike was a Vice President and research analyst at Steeple Capital (September 2005 through March 2007), where he covered the biotechnology, biopharmaceuticals, research tools and diagnostics industries. Prior to Steeple, he was the medical devices analyst at Welch Capital Partners and an associate

Ohad Hammer

Ohad is a Partner at Pontifax, where he is focused on scouting and project evaluation. He also serves on the board of several of Pontifax’s portfolio companies including AgomAb, Precirix, Step Pharma, Pi Therapeutics and Kamari Pharma. Ohad obtained his MSc in Biology from Tel-Aviv University.

Tim Knotnerus

Tim is CEO and member of the Board of Directors of Agomab, a Belgian biotech company focusing on growth factor biology and developing therapeutics for fibrotic indications. Together with the team, he has raised around $140M from top US and EU investors since joining Agomab in 2019. Prior to Agomab, Tim held the position of

By continuing to use the site, you agree to the use of cookies. Privacy Policy

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.